Factors | No. of patients | Overall survival (OS) | Progression-free survival (DFS) | ||
---|---|---|---|---|---|
1-year OS rate (%) | p-value | 1-year PFS rate (%) | p-value | ||
Age | |||||
>ā60 | 19 | 67 | 0.43 | 45 | 0.93 |
ā¦ā60 | 25 | 62 | 35 | ||
Clinical T classification | |||||
T1/2 | 3 | 66 | 0.83 | 66% | 0.46 |
T3/4 | 41 | 64 | 37% | ||
Clinical N classification | |||||
N0 | 4 | 67 | 0.90 | 25% | 0.60 |
N positive | 40 | 64 | 42% | ||
Tumor grade | |||||
Grade 1 | 4 | 100 | 0.18 | 75 | 0.019* |
Grade 2 | 34 | 62 | 41 | ||
Grade 3 | 6 | 50 | 0 | ||
Primary tumor location | |||||
Cervical | 3 | 100 | 0.11 | 0 | 0.18 |
Upper | 11 | 40 | 18 | ||
Middle | 18 | 71 | 49 | ||
Lower | 12 | 66 | 50 | ||
Resection or Systemic Treatment | |||||
Resection | 14 | 100 | <ā0.0001* | 48 | 0.038* |
Only Systemic Treatment | 30 | 49 | 33 | ||
Performance Status | |||||
0 | 39 | 70 | <ā0.0001* | 45 | 0.0024* |
1 | 4 | 25 | 0 | ||
2 | 1 | 0 | 0 | ||
Lung Metastasis Number | |||||
1 | 16 | 75 | 0.061 | 35 | 0.6032 |
2 | 7 | 67 | 40 | ||
3 | 2 | 100 | 100 | ||
4 | 2 | 100 | 100 | ||
>=5 | 17 | 44 | 34 |